JPWO2020185750A5 - - Google Patents

Info

Publication number

JPWO2020185750A5

JPWO2020185750A5 JP2021554699A JP2021554699A JPWO2020185750A5 JP WO2020185750 A5 JPWO2020185750 A5 JP WO2020185750A5 JP 2021554699 A JP2021554699 A JP 2021554699A JP 2021554699 A JP2021554699 A JP 2021554699A JP WO2020185750 A5 JPWO2020185750 A5 JP WO2020185750A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

concentration

lingo

seq

antibody

Prior art date

2023-03-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 86
• 239000012634 fragment Substances 0.000 claims description 24
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 16
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 16
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 16
• 229920000053 polysorbate 80 Polymers 0.000 claims description 16
• 229940068968 polysorbate 80 Drugs 0.000 claims description 16
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 12
• 229960003589 arginine hydrochloride Drugs 0.000 claims description 12
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 8
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 8
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 8
• 239000003795 chemical substances by application Substances 0.000 claims description 8
• 230000002519 immonomodulatory effect Effects 0.000 claims description 8
• 229930182817 methionine Natural products 0.000 claims description 8
• 239000000203 mixture Substances 0.000 claims description 8
• 208000016192 Demyelinating disease Diseases 0.000 claims description 6
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 4
• 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 claims description 4
• 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 claims description 4
• 108010072051 Glatiramer Acetate Proteins 0.000 claims description 4
• 108010005716 Interferon beta-1a Proteins 0.000 claims description 4
• 108010005714 Interferon beta-1b Proteins 0.000 claims description 4
• 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 4
• 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 4
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 4
• 229960000548 alemtuzumab Drugs 0.000 claims description 4
• 229960002436 cladribine Drugs 0.000 claims description 4
• LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 4
• 229960004419 dimethyl fumarate Drugs 0.000 claims description 4
• 229960000556 fingolimod Drugs 0.000 claims description 4
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 4
• 229960003776 glatiramer acetate Drugs 0.000 claims description 4
• 239000003112 inhibitor Substances 0.000 claims description 4
• 229960004461 interferon beta-1a Drugs 0.000 claims description 4
• 229960003161 interferon beta-1b Drugs 0.000 claims description 4
• 238000001990 intravenous administration Methods 0.000 claims description 4
• 229960005027 natalizumab Drugs 0.000 claims description 4
• 229950005751 ocrelizumab Drugs 0.000 claims description 4
• 229960001291 peginterferon beta-1a Drugs 0.000 claims description 4
• 108010027737 peginterferon beta-1a Proteins 0.000 claims description 4
• 150000003431 steroids Chemical class 0.000 claims description 4
• QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
• 208000003435 Optic Neuritis Diseases 0.000 claims description 2
• 239000012458 free base Substances 0.000 claims description 2
• 238000007918 intramuscular administration Methods 0.000 claims description 2
• 201000006417 multiple sclerosis Diseases 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
• 238000000034 method Methods 0.000 description 10
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1